A novel strategy for treating oncogene-mutated tumors by targeting tumor microenvironment and synergistically enhancing anti-PD-1 immunotherapy
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Cancer communications (London, England) - 44(2024), 3 vom: 25. März, Seite 438-442 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Yingqiang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 25.03.2024 Date Revised 25.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cac2.12521 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368246515 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368246515 | ||
| 003 | DE-627 | ||
| 005 | 20240325234815.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240210s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cac2.12521 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1346.xml |
| 035 | |a (DE-627)NLM368246515 | ||
| 035 | |a (NLM)38335159 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Yingqiang |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A novel strategy for treating oncogene-mutated tumors by targeting tumor microenvironment and synergistically enhancing anti-PD-1 immunotherapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2024 | ||
| 500 | |a Date Revised 25.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 700 | 1 | |a Tong, Linjiang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Mengge |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Qiupei |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Lai, Mengzhen |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Haotian |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Geng, Meiyu |e verfasserin |4 aut | |
| 700 | 1 | |a Duan, Wenhu |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Hua |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer communications (London, England) |d 2018 |g 44(2024), 3 vom: 25. März, Seite 438-442 |w (DE-627)NLM28410809X |x 2523-3548 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2024 |g number:3 |g day:25 |g month:03 |g pages:438-442 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cac2.12521 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2024 |e 3 |b 25 |c 03 |h 438-442 | ||